Eli Lily On Thursday I mentioned Mixed results For the fourth quarter, even with the high sales of drugs that lose weight and treat diabetes.
The company’s quarterly profits topped the Wall Street estimates, but sales decreased short, as Monjao witnessed lower prices. Zepbound and Mountjaro now have low -performance forecasts for forty consecutive, as the company was previously indicated to it. Issues related to stocks decrease Among the wholesalers.
The giant pharmaceutical company also issued a financial profit directives 2025 from 22.05 dollars to $ 23.55 per share, which is in line with what analysts expect. Eli Lily launched her financial sales directives 2025 from $ 58 billion to $ 61 billion.
The numbers were consistent with the initial results that Elie Lily participated in January, which was disappointed. Elie Lily was It reduced its revenue directions for 2024He also said that the demand for weight loss and diabetes will not fulfill its noble expectations.
It is worth noting that Elie Lily said that she plans to report the data of the late stage of obesity from the next generation Retras Later this year, a few months ago what was expected. Retatrutide works differently from any of the treatments on the market, simulating three different hormones: GLP-1, GIP and Glucagon.
Here is what Elie Lily told for the fourth quarter compared to what Wall Street expected, based on a survey of analysts by LSEG:
- Arrow’s profits: 5.32 average $ 4.95 expected
- profit: 13.53 billion dollars compared to 13.57 billion dollars expected
The company recorded the fourth -quarter revenues of $ 13.53 billion, an increase of 45 % over the same period.
The pharmaceutical giant of the net income of $ 4.41 billion, or $ 4.88 per share, for the fourth quarter. This compares with a profit of $ 2.19 billion, or $ 2.42 per share, a year ago.
With the exception of the one -time items related to the value of unfinished assets and other assessments, El Lilly has published $ 5.32 per share per share for the fourth quarter of 2024.
Zepbound, Mountaro Performance
Mounjaro 3.53 billion dollars in revenue for the fourth quarter, an increase of 60 % over the most colloquial period. Analysts expected the drug to reserve $ 3.62 billion in sales for a quarter, according to Streetaccount.
Elie Lily said that the increase reflects the strong demand and the increase of the supply from Mountrao, but was partly compensated by the low prices achieved due to the “favorable changes” in the fourth quarter of 2023 for discounts and discounts.
Meanwhile, the results were the first full year for Zepbound in the United States market. The weekly injection achieved $ 1.91 billion in sales for the fourth quarter, which is less than $ 1.98 billion expected by analysts, according to Streetaccount.
But the demand in the United States still outperformed Eli Lily’s drugs, such as Zepbound and Mountjaro, last year. Both remedies mimic some bowel hormones to reduce a person’s appetite and regulate blood sugar.
The popularity of these injection drugs has forced both Eli Lily and her opponent Novo Nordsk To invest billions of dollars to increase the manufacturing capacity to treat it. It seems that efforts are paid off: Food and Drug Administration in December Reaffirm To announce the American deficiency in Turzopatide – the active ingredient in Zepbound and Mounjaro – End.
On Thursday, Elie Lily estimated that she would produce at least 1.6 times the amount of the duct doses in the first half of 2025 compared to the first half of 2024.
The results also begin a decisive year for Eli Lilly, which is scheduled to issue clinical experience that is closely monitored on experimental obesity pills, Orforglipron. These results are expected by mid -year.
This story is developing. Please check again for updates.
https://image.cnbcfm.com/api/v1/image/107386526-17102774692023-03-01t183627z_95571214_rc24lz9u1qcj_rtrmadp_0_lilly-insulin.jpeg?v=1738097880&w=1920&h=1080
Source link